EA031106B1 - Диоксолановые аналоги уридина для лечения рака - Google Patents

Диоксолановые аналоги уридина для лечения рака Download PDF

Info

Publication number: EA031106B1
Authority: EA; Eurasian Patent Office
Prior art keywords: mmol; alkyl; dia; mixture; compound
Prior art date: 2014-08-25

Application number

EA201790328A

Other languages

English (en)

Russian (ru)

Other versions

EA201790328A1 (ru

Inventor

Рикард Бетель

Андеш Энерот

Бьерн Классон

Фредрик Эберг

Original Assignee

Медивир Аб

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-25

Filing date

2015-08-24

Publication date

2018-11-30

2015-08-24 Application filed by Медивир Аб filed Critical Медивир Аб

2017-08-31 Publication of EA201790328A1 publication Critical patent/EA201790328A1/ru

2018-11-30 Publication of EA031106B1 publication Critical patent/EA031106B1/ru

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

EA201790328A 2014-08-25 2015-08-24 Диоксолановые аналоги уридина для лечения рака EA031106B1 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE1450983		2014-08-25
SE1550858		2015-06-22
PCT/EP2015/069370 WO2016030335A1 (en)	2014-08-25	2015-08-24	Dioxolane analogues of uridine for the treatment of cancer

Publications (2)

Publication Number	Publication Date
EA201790328A1 EA201790328A1 (ru)	2017-08-31
EA031106B1 true EA031106B1 (ru)	2018-11-30

Family

ID=54014804

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EA201790328A EA031106B1 (ru)	2014-08-25	2015-08-24	Диоксолановые аналоги уридина для лечения рака
EA201890648A EA033300B1 (ru)	2014-08-25	2015-08-24	Диоксолановые аналоги уридина для лечения рака

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EA201890648A EA033300B1 (ru)	2014-08-25	2015-08-24	Диоксолановые аналоги уридина для лечения рака

Country Status (24)

Country	Link
US (7)	US10144750B2 (2)
EP (2)	EP3186244B1 (2)
JP (2)	JP6663424B2 (2)
KR (2)	KR102396905B1 (2)
CN (4)	CN110790789B (2)
AU (2)	AU2015308988C1 (2)
BR (1)	BR112017003898B1 (2)
CA (2)	CA2956251C (2)
CY (1)	CY1122945T1 (2)
DK (2)	DK3572410T3 (2)
EA (2)	EA031106B1 (2)
ES (2)	ES2927212T3 (2)
HR (1)	HRP20201023T1 (2)
HU (2)	HUE050705T2 (2)
IL (2)	IL250344B (2)
MX (1)	MX369649B (2)
MY (2)	MY188089A (2)
NZ (2)	NZ729118A (2)
PH (2)	PH12017500184A1 (2)
PL (2)	PL3572410T3 (2)
PT (2)	PT3186244T (2)
SG (3)	SG11201701172SA (2)
WO (1)	WO2016030335A1 (2)
ZA (1)	ZA201802864B (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ729118A (en) *	2014-08-25	2022-02-25	Medivir Ab	Dioxolane analogues of uridine for the treatment of cancer
CN106543220A (zh) *	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	氨基磷酸酯化合物及其制备方法和晶体
RS62593B1 (sr) *	2015-12-11	2021-12-31	NuCana plc	Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031
CA3014769C (en) *	2016-03-02	2024-01-09	Medivir Aktiebolag	Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CN106432328B (zh) *	2016-09-14	2019-03-22	江苏福瑞生物医药有限公司	一种索非布韦中间体的制备方法
CA3043437A1 (en) *	2016-11-18	2018-05-24	Neurovive Pharmaceutical Ab	Liver prodrugs of mitochondrial proton ionophores
GB201709471D0 (en) *	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
WO2019245444A1 (en)	2018-06-21	2019-12-26	Medivir Ab	Base-modified cytidine nucleotides for leukemia therapy
JP7337539B2 (ja) *	2018-06-21	2023-09-04	メディヴィル・アクチエボラーグ	白血病療法のための塩基修飾シチジンヌクレオチド
CN113453685A (zh) *	2019-02-18	2021-09-28	美迪维尔公司	使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
CN110964057B (zh) *	2019-12-25	2022-05-06	东南大学	一种利用微流体反应装置制备索非布韦中间体的方法
CN113402546A (zh) *	2020-03-17	2021-09-17	浙江四维医药科技有限公司	一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
HUE071473T2 (hu) *	2020-04-15	2025-09-28	Medivir Ab	MIV-818/lenvatinib kombinációs terápia májrák kezelésére
CN113754692B (zh) *	2020-06-03	2022-06-10	上海交通大学	瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114380860A (zh) *	2020-10-22	2022-04-22	广东东阳光药业有限公司	一种含磷化合物的制备方法
CN114685558A (zh) *	2020-12-28	2022-07-01	尚科生物医药（上海）有限公司	一种瑞德西韦中间体的制备方法
CN114249764A (zh) *	2021-11-10	2022-03-29	宁波大学	一种磷酰胺酯类前药的中间体及其制备方法与应用
WO2025155547A1 (en) *	2024-01-17	2025-07-24	University Of Georgia Research Foundation, Inc.	An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane
CN119240898A (zh) *	2024-11-21	2025-01-03	中冶赛迪工程技术股份有限公司	适用于连续流污水处理的精准调酸系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002030922A2 (en) *	2000-10-13	2002-04-18	Shire Biochem Inc.	Dioxolane analogs for improved inter-cellular delivery
WO2005012327A2 (en) *	2003-07-21	2005-02-10	University College Cardiff Consultants Limited	Nucleotide phosphoramidates as anticancer agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5444063A (en) *	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en)	1996-11-15	2000-02-08	Yale University	L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
WO2007106450A2 (en) *	2006-03-10	2007-09-20	University Of Georgia Research Foundation, Inc.	Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
KR20090057050A (ko)	2006-09-01	2009-06-03	유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드	암치료를 위한 트록사시타빈 전구약물
PL216525B1 (pl) *	2006-10-17	2014-04-30	Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk	5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) *	2011-12-05	2013-06-06	Medivir Ab	HCV Polymerase Inhibitors
CN105934438A (zh) *	2013-11-27	2016-09-07	艾登尼克斯药业有限公司	用于治疗肝癌的核苷酸
NZ729118A (en) *	2014-08-25	2022-02-25	Medivir Ab	Dioxolane analogues of uridine for the treatment of cancer

2015
- 2015-08-24 NZ NZ729118A patent/NZ729118A/en unknown
- 2015-08-24 MX MX2017002328A patent/MX369649B/es active IP Right Grant
- 2015-08-24 EA EA201790328A patent/EA031106B1/ru not_active IP Right Cessation
- 2015-08-24 DK DK19177824.0T patent/DK3572410T3/da active
- 2015-08-24 US US15/506,692 patent/US10144750B2/en active Active
- 2015-08-24 HU HUE15756888A patent/HUE050705T2/hu unknown
- 2015-08-24 PT PT157568882T patent/PT3186244T/pt unknown
- 2015-08-24 CA CA2956251A patent/CA2956251C/en active Active
- 2015-08-24 PT PT191778240T patent/PT3572410T/pt unknown
- 2015-08-24 EA EA201890648A patent/EA033300B1/ru not_active IP Right Cessation
- 2015-08-24 ES ES19177824T patent/ES2927212T3/es active Active
- 2015-08-24 CA CA3128645A patent/CA3128645C/en active Active
- 2015-08-24 WO PCT/EP2015/069370 patent/WO2016030335A1/en not_active Ceased
- 2015-08-24 MY MYPI2017700615A patent/MY188089A/en unknown
- 2015-08-24 SG SG11201701172SA patent/SG11201701172SA/en unknown
- 2015-08-24 AU AU2015308988A patent/AU2015308988C1/en active Active
- 2015-08-24 SG SG10201911558UA patent/SG10201911558UA/en unknown
- 2015-08-24 DK DK15756888.2T patent/DK3186244T3/da active
- 2015-08-24 CN CN201911148331.9A patent/CN110790789B/zh active Active
- 2015-08-24 PL PL19177824.0T patent/PL3572410T3/pl unknown
- 2015-08-24 HR HRP20201023TT patent/HRP20201023T1/hr unknown
- 2015-08-24 KR KR1020177008235A patent/KR102396905B1/ko active Active
- 2015-08-24 SG SG10202001117YA patent/SG10202001117YA/en unknown
- 2015-08-24 JP JP2017511226A patent/JP6663424B2/ja active Active
- 2015-08-24 EP EP15756888.2A patent/EP3186244B1/en active Active
- 2015-08-24 ES ES15756888T patent/ES2796089T3/es active Active
- 2015-08-24 HU HUE19177824A patent/HUE059640T2/hu unknown
- 2015-08-24 KR KR1020207008682A patent/KR102398714B1/ko active Active
- 2015-08-24 CN CN201911149251.5A patent/CN110804072B/zh active Active
- 2015-08-24 BR BR112017003898-6A patent/BR112017003898B1/pt active IP Right Grant
- 2015-08-24 CN CN201580056640.7A patent/CN107074826B/zh active Active
- 2015-08-24 PL PL15756888T patent/PL3186244T3/pl unknown
- 2015-08-24 NZ NZ762628A patent/NZ762628A/en unknown
- 2015-08-24 CN CN202010199579.4A patent/CN111269264A/zh active Pending
- 2015-08-24 EP EP19177824.0A patent/EP3572410B1/en active Active
2017
- 2017-01-30 IL IL250344A patent/IL250344B/en active IP Right Grant
- 2017-01-31 PH PH12017500184A patent/PH12017500184A1/en unknown
- 2017-02-22 MY MYPI2021007010A patent/MY198325A/en unknown
2018
- 2018-03-20 AU AU2018201980A patent/AU2018201980B2/en active Active
- 2018-05-02 ZA ZA2018/02864A patent/ZA201802864B/en unknown
- 2018-12-03 US US16/208,083 patent/US10336780B2/en active Active
2019
- 2019-05-21 IL IL266766A patent/IL266766B/en active IP Right Grant
- 2019-07-01 US US16/459,165 patent/US10654877B2/en active Active
- 2019-08-19 PH PH12019501919A patent/PH12019501919A1/en unknown
2020
- 2020-02-14 JP JP2020023051A patent/JP6905609B2/ja active Active
- 2020-04-13 US US16/847,477 patent/US10822360B2/en active Active
- 2020-05-22 CY CY20201100469T patent/CY1122945T1/el unknown
- 2020-11-02 US US17/087,483 patent/US11447511B2/en active Active
2022
- 2022-09-19 US US17/948,050 patent/US20230117570A1/en not_active Abandoned
2023
- 2023-05-31 US US18/326,992 patent/US20230382931A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002030922A2 (en) *	2000-10-13	2002-04-18	Shire Biochem Inc.	Dioxolane analogs for improved inter-cellular delivery
WO2005012327A2 (en) *	2003-07-21	2005-02-10	University College Cardiff Consultants Limited	Nucleotide phosphoramidates as anticancer agents

Also Published As

Publication number	Publication date
JP6905609B2 (ja)	2021-07-21
NZ762628A (en)	2023-04-28
AU2018201980A1 (en)	2018-04-12
US10336780B2 (en)	2019-07-02
EP3186244B1 (en)	2020-04-22
JP2020090535A (ja)	2020-06-11
AU2018201980B2 (en)	2019-05-16
AU2015308988A1 (en)	2017-02-23
CN107074826B (zh)	2020-05-22
US20200239502A1 (en)	2020-07-30
MX369649B (es)	2019-11-15
BR112017003898A2 (pt)	2017-12-05
CA2956251C (en)	2022-10-25
PH12017500184B1 (en)	2017-06-28
US10822360B2 (en)	2020-11-03
CA3128645A1 (en)	2016-03-03
EA033300B1 (ru)	2019-09-30
SG11201701172SA (en)	2017-03-30
ES2927212T3 (es)	2022-11-03
SG10202001117YA (en)	2020-04-29
CN107074826A (zh)	2017-08-18
US20210054008A1 (en)	2021-02-25
ZA201802864B (en)	2019-07-31
SG10201911558UA (en)	2020-01-30
US20170267705A1 (en)	2017-09-21
EP3572410B1 (en)	2022-07-20
KR20200035482A (ko)	2020-04-03
AU2015308988C1 (en)	2018-09-06
HUE050705T2 (hu)	2020-12-28
CN110804072A (zh)	2020-02-18
EP3186244A1 (en)	2017-07-05
MY188089A (en)	2021-11-17
NZ729118A (en)	2022-02-25
MX2017002328A (es)	2017-05-22
US20230382931A1 (en)	2023-11-30
DK3186244T3 (da)	2020-07-13
MY198325A (en)	2023-08-24
US20230117570A1 (en)	2023-04-20
KR20170046736A (ko)	2017-05-02
PL3572410T3 (pl)	2022-10-03
HRP20201023T1 (hr)	2020-10-16
JP6663424B2 (ja)	2020-03-11
IL266766A (en)	2019-07-31
IL250344A0 (en)	2017-03-30
CN111269264A (zh)	2020-06-12
WO2016030335A1 (en)	2016-03-03
EA201790328A1 (ru)	2017-08-31
EA201890648A2 (ru)	2018-08-31
US10144750B2 (en)	2018-12-04
EA201890648A3 (ru)	2019-02-28
PL3186244T3 (pl)	2020-11-16
US20190389890A1 (en)	2019-12-26
CY1122945T1 (el)	2021-10-29
US20190100541A1 (en)	2019-04-04
IL266766B (en)	2020-05-31
EP3572410A1 (en)	2019-11-27
HUE059640T2 (hu)	2022-12-28
IL250344B (en)	2020-01-30
JP2017526677A (ja)	2017-09-14
BR112017003898B1 (pt)	2022-10-18
DK3572410T3 (da)	2022-08-29
PH12017500184A1 (en)	2017-06-28
KR102398714B1 (ko)	2022-05-17
US10654877B2 (en)	2020-05-19
ES2796089T3 (es)	2020-11-25
US11447511B2 (en)	2022-09-20
AU2015308988B2 (en)	2018-04-26
PT3572410T (pt)	2022-09-15
CN110790789B (zh)	2023-05-12
PH12019501919A1 (en)	2020-09-14
CN110790789A (zh)	2020-02-14
CN110804072B (zh)	2023-05-12
CA3128645C (en)	2023-06-27
PT3186244T (pt)	2020-05-29
CA2956251A1 (en)	2016-03-03
KR102396905B1 (ko)	2022-05-13

Legal Events

Date	Code	Title	Description
2020-03-31	MM4A	Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)	Designated state(s): AM AZ BY KZ KG TJ TM

Publication	Publication Date	Title
JP6905609B2 (ja)	2021-07-21	癌の処置のためのウリジンのジオキソラン類似体
TWI687431B (zh)	2020-03-11	治療癌症之前藥
HK40014376B (en)	2023-08-04	Dioxolane analogues of uridine for the treatment of cancer
HK40020872A (en)	2020-10-30	Dioxolane analogues of uridine for the treatment of cancer
HK40014377B (en)	2023-08-04	Dioxolane analogues of uridine for the treatment of cancer
HK40014377A (en)	2020-08-21	Dioxolane analogues of uridine for the treatment of cancer
HK40014376A (en)	2020-08-21	Dioxolane analogues of uridine for the treatment of cancer
HK40011623B (en)	2022-11-04	Dioxolane analogues of uridine for the treatment of cancer
HK40011623A (en)	2020-07-17	Dioxolane analogues of uridine for the treatment of cancer
HK1235405A1 (en)	2018-03-09	Dioxolane analogues of uridine for the treatment of cancer
HK1240591A1 (en)	2018-05-25	Dioxolane analogues of uridine for the treatment of cancer
HK1240591B (en)	2021-01-08	Dioxolane analogues of uridine for the treatment of cancer